Table 3 Survey Respondent Characteristics
Variable | n | % | n | % | n | % |
|---|---|---|---|---|---|---|
State/Territory (n = 265/5700) | Clozapine Service a (n = 136) | No Servicea (n = 129) | ||||
Queensland | 69 | 26.0 | 33 | 47.8 | 36 | 52.2 |
New South Wales | 67 | 25.3 | 41 | 61.2 | 26 | 38.8 |
Victoria | 45 | 17.0 | 22 | 48.9 | 23 | 51.1 |
Western Australia | 42 | 15.9 | 18 | 42.9 | 24 | 57.1 |
South Australia | 22 | 8.3 | 15 | 68.2 | 7 | 31.8 |
Australian Capital Territory | 7 | 2.6 | 5 | 71.4 | 2 | 28.6 |
Tasmania | 5 | 1.9 | 1 | 20.0 | 4 | 80.0 |
Northern Territory | 3 | 1.1 | – | – | 3 | 100.0 |
Unknown | 5 | 1.9 | 1 | 25.0 | 4 | 75.0 |
Professional Pharmacy Services provided (n = 263/265) | Clozapine Service b (n = 136/136) | No Service b (n = 127/129) | ||||
Dose Administration Aids | 254 | 96.6 | 132 | 97.1 | 122 | 96.1 |
MedsCheckc | 234 | 89.0 | 119 | 87.5 | 115 | 90.6 |
Home Medicines Reviewsd | 169 | 64.3 | 94 | 69.1 | 75 | 59.1 |
Opioid Substitution Therapy | 135 | 51.3 | 76 | 55.9 | 59 | 46.5 |
Harm Reductione | 133 | 50.6 | 71 | 52.2 | 62 | 48.8 |
Pain Managementf | 86 | 32.7 | 44 | 32.4 | 42 | 33.1 |
Diabetes Screening Trialg | 58 | 22.1 | 29 | 21.3 | 29 | 22.8 |
RMMRh | 41 | 15.6 | 26 | 19.1 | 15 | 11.8 |
Aboriginal Health Servicesi | 32 | 12.2 | 14 | 10.3 | 18 | 14.2 |
None | 3 | 1.1 | 2 | 1.5 | 1 | 0.8 |
Otherj | 33 | 12.5 | 15 | 11.0 | 18 | 14.2 |